2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1385

Increased Body Mass Index in Ankylosing Spondylitis Is Associated with a Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise
Abstract Number: 662

Increased C1q, C4 and C3 Deposition On Platelets in Patients with Systemic Lupus Erythematosus – A Possible Link to Venous Thrombosis?
Abstract Number: 1533

Increased Circulating FoxP3⁺ T-Cells in Patients with Granulomatosis with Polyangiitis Are Attributed to an Increase in the Non-Suppressor FoxP3^Low CD45RO⁺ T_Reg Cell Subpopulation
Abstract Number: 605

Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1942

Increased Levels of Eotaxin and MCP-1 in Juvenile Dermatomyositis Median 17 Years After Diagnosis; Associations with Disease Activity, Duration and Organ Damage
Abstract Number: 2309

Increased Levels of Ser 181 Phosphorylated SOX9 in SSc Dermal Fibroblasts: A Novel Participant in the Pathogenesis of SSc Fibrotic Process
Abstract Number: 649

Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus
Abstract Number: 965

Increased Number of Painful Body Sites Is Associated with Worse Pain and Disability-Associated Outcomes Among Returning Operations Enduring Freedom/Operation Iraqi Freedom Service Members
Abstract Number: 1073

Increased Oxidative Burst in Neutrophils but Not Monocytes in Systemic Lupus Erythematosus
Abstract Number: 1372

Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Abstract Number: 1501

Increased Periostin Levels in Patients with Systemic Sclerosis
Abstract Number: 67

Increased Prevalence of Hypothyroidism Preceding Rheumatoid Arthritis – an Epidemiological Study
Abstract Number: 1881

Increased Psychosocial Stress Is a Major Component of Fibromyalgia Triggers
Abstract Number: 746

Increased Risk of Acute and Chronic Renal Comorbidity in Ankylosing Spondylitis: Results From a Population-Based Study
Abstract Number: 1684

Increased Risk of Major Cardiovascular Events in a Nationwide Cohort of Rheumatoid Arthritis Patients Treated with Biological Agents

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].